Weill Cornell Medicine ELab
Event Address

Belfer Research Building - Weill Cornell Medicine, Room 302
413 E 69th Street
New York, NY 10021
United States

Event Date

Phil Crowley, Former Assistant General Counsel, Johnson & Johnson; Biotech Startup Consultant

George W. Johnston, Counsel, Intellectual Property, Gibbons; former Chief Patent Counsel for Hoffmann-La Roche Inc.

This one-hour lecture with Q&A will cover the basics to consider when forming a biotech startup.

Refreshments will be served.





Phil Crowley, Former Assistant General Counsel, Johnson & Johnson; Biotech Startup Consultant

Philip P. Crowley is former Assistant General Counsel of Johnson & Johnson, the world’s most diversified healthcare products company. Phil served in the Law Department for over 30 years handling a broad array of mergers and acquisitions, licensing agreements, venture capital investments, commercial transactions, corporate governance and securities matters. He also served for a time as the principal counsel to J&J’s biotech companies on FDA regulatory matters.

Phil has been a member of the Board of Trustees of Stevens Institute of Technology for 25 years, where he serves on the Research Enterprise and Technology Commercialization Committee. He is a director for Brightflag LTD (Ireland), an emerging IT company using artificial intelligence on a “software-as-a-service” platform for corporate law departments and law firms. He is an Entrepreneur in Residence at the New Jersey Institute of Technology Enterprise Development Center and an Angel investor with the NJIT Highlanders Angel Network. Phil serves as a mentor at the Entrepreneurs Roundtable Accelerator in NYC and here at the Bench to Bedside Initiative.

He earned a B.S. in physics from Stevens Institute of Technology, an M.S. in applied physics from Harvard University and a J.D. from Columbia Law School.

George W. Johnston, Counsel, Intellectual Property, Gibbons; former Chief Patent Counsel for Hoffmann-La Roche Inc.

Mr. Johnston focuses his practice on the preparation, prosecution, licensing, and litigation of patents, as well as counseling on intellectual property matters, with a particular focus in the pharmaceutical and biotechnology industries. Prior to joining Gibbons, Mr. Johnston served as Vice President and Chief Patent Counsel at Hoffmann-La Roche Inc., a major healthcare organization, having ascended through the ranks from Patent Counsel. At Roche, Mr. Johnston developed and implemented a variety of strategies to strengthen the company’s intellectual property throughout the life cycle of its products. For several important pharmaceuticals, he enabled Roche to maintain lawful exclusivity for 20 years and beyond, and he won or settled the majority of the company’s patent litigations, ensuring marketing exclusivity and corresponding sales and licensing royalties worth billions of dollars. He negotiated and prepared the company’s first successful co-promotion alliance agreement, leading to half a billion dollars in revenue. Mr. Johnston was also extensively involved in legislative activities benefiting the pharmaceutical industry. Most notably, he helped negotiate and lobby Congress to pass both the Hatch-Waxman Act (and led Roche’s successful efforts to obtain one of the first resulting patent extensions) and Process Patent Amendments Act. In addition, his creative approach for petitioning the FDA led to Roche becoming one of the first companies to obtain pediatric exclusivity rights.